Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nanyoung Park

Clinical Nurse Specialist, Adult Health Duluth, GA Nurse Practitioner

NPI 1043633084 CMS profile 11241104

3590 Peachtree Industrial Blvd, Duluth, GA 30096

Open in the dashboard

General payments

$8,882

398 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nanyoung Park of Duluth, GA is reported in the CMS Open Payments database as having received $8,882 across 398 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,410 92
2024 General $2,361 102
2023 General $2,205 111
2022 General $1,334 65
2021 General $572 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nanyoung Park
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Nanyoung Park were reported at $2,410. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Nanyoung Park Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $572 $133 $48–$445 $132
2022 $1,334 $163 $57–$526 $149
2023 $2,205 $173 $64–$597 $160
2024 $2,361 $171 $54–$575 $164
2025 $2,410 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Merck Sharp & Dohme Corporation $655 23 payments
  2. AstraZeneca Pharmaceuticals LP $612 28 payments
  3. Janssen Biotech, Inc. $609 28 payments
  4. Novartis Pharmaceuticals Corporation $554 26 payments
  5. Celgene Corporation $494 23 payments
  6. Seattle Genetics, Inc. $424 22 payments
  7. Daiichi Sankyo Inc. $423 17 payments
  8. Pfizer Inc. $415 25 payments
  9. Genentech USA, Inc. $296 14 payments
  10. Eisai Inc. $244 10 payments
  11. Other $4,156 182 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,787 397 payments
  2. Education $95 1 payment
Products named General payments · program years 2021–2025
  1. KEYTRUDA $628 22 payments
  2. REBLOZYL $356 14 payments
  3. DARZALEX $332 14 payments
  4. ENHERTU $306 11 payments
  5. BRUKINSA $248 11 payments
  6. IMBRUVICA $246 9 payments
  7. LYNPARZA $245 13 payments
  8. Lenvima $244 10 payments
  9. WELIREG $236 8 payments
  10. TUKYSA $220 13 payments
  11. Other $7,537 353 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

288

Median for Nurse Practitioner: 389

Drug cost

$572,084

Median for Nurse Practitioner: $21,885

Branded share of claims

28.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doptelet Avatrombopag Maleate Brand 13 $326,365
Jakafi Ruxolitinib Phosphate Brand 11 $204,602
Imatinib Mesylate Generic 14 $20,382
Eliquis Apixaban Brand 17 $9,278
Tenofovir Disoproxil Fumarate Generic 13 $7,358
Exemestane Generic 11 $1,858
Anastrozole Generic 70 $860
Valacyclovir Valacyclovir Hcl Brand 20 $498
Dexamethasone Generic 31 $304
Ondansetron Odt Ondansetron Brand 20 $156

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$14,528

Medicare's payments for the services billed

Medicare patients

81

Average age 75

Services billed

290

45 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 52%
Arthritis 47%
Chronic kidney disease 35%
Ischemic heart disease 33%
Diabetes 32%
Heart failure 17%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 56 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $151
$151 — —
ENHERTU
  • Daiichi Sankyo Inc. $70
  • AstraZeneca Pharmaceuticals LP $50
$120 — —
IMBRUVICA
  • AbbVie, Inc. $75
  • Janssen Biotech, Inc. $14
$89 — —
OJJAARA
  • GlaxoSmithKline, LLC. $82
$82 — —
Lenvima
  • Eisai Inc. $77
$77 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 56 with Patron

Records

398 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record